Transesophageal Echocardiography (ACUTE) trial was the first randomized prospective study to compare the conventional strategy of 3 weeks of anticoagulation before direct current cardioversion (DCC) for atrial fibrillation (AF) to a transesophageal echocardiography (TEE) guided approach with an expedited course of anticoagulation. This was a multicenter, international study with 70 sites enrolling 1222 patients between 1994-1999. The primary endpoint of composite embolic events and secondary endpoints including bleeding, functional status, prevalence of sinus rhythm, and death were assessed at 8 weeks following randomization.
Introduction
Management paradigms for persistent atrial fibrillation (AF) continue to emerge with the potential for "curative therapy" with pulmonary vein isolation or the MAZE procedure and the option of "rate control" and anticoagulation [1] [2] [3] . While these alternatives represent destination therapy for a small proportion of patients with AF, the treatment goal for the vast majority is to attempt to restore sinus rhythm (SR) with pharmacologic or direct current cardioversion (DCC). Two strategies have evolved to prevent thromboembolism after cardioversion for patients with AF greater than 48 hours. The conventional approach uses 3 weeks of anticoagulation before and 4 weeks after DCC [4] . The newer transesophageal echocardiography (TEE) guided approach that has been utilized for the past 10 years allows for a shorter course of therapeutic anticoagulation prior to DCC if no left atrial thrombus is present [5] . This article reviews the results of the Assessment of Cardioversion Using Transesophageal Echocardiography (ACUTE) trial, the first randomized prospective study to compare these strategies [6] .
Background: TEE Guided Strategy
Although the American College of Chest Physicians has supported the conventional approach for the past 30 years, the data defending this strategy is drawn mostly from observational studies [4, 7] . The advent of TEE and its capability to exclude left atrial thrombus with greater than 95% accuracy gave rise to an alternative approach [8] [9] [10] . The primary benefit of a TEE guided strategy was a shorter course of anticoagulation and a more expedited restoration of SR. Small nonrandomized studies during the past decade demonstrated that this was as safe as the conventional approach with low rates of thromboembolism [11, 12] . An additional early lesson learned following TEE guided DCC was that a period of 4 weeks of anticoagulation following achievement of sinus rhythm was still required even if no thrombus was present, due to the potential for subsequent thrombus formation during atrial stunning [13] [14] [15] .
ACUTE Trial Design
The ACUTE trial was an investigator-initiated, randomized, multicenter study taking place in 70 clinical sites [6] . A total of 1222 patients (619-TEE guided approach and 603 conventional approach) were enrolled between 1994-1999. The Data and Safety Monitoring Board discontinued the study prior to reaching the intended sample size of 3000 patients due to low numbers of recruitment and embolic events.
The study protocol and inclusion criteria are shown in Figure 1 . Excluded from the study were patients who were hemodynamically unstable, those with isolated atrial flutter, on long-term anticoagulation or with a contraindication to either warfarin or TEE.
The primary end point of the study was an embolic event (stroke, transient ischemic attack, or peripheral embolism). Secondary end points included minor or major bleeding, functional status, presence of sinus rhythm, relative costs and death. The followup period was 8 weeks from the time of randomization though 6-month outcomes were subsequently reported.
The baseline clinical and echocardiographic characteristics were similar for each group: mean age 64 years (66% male), mean left ventricular ejection fraction of 50%, median duration of AF of 13 days and advanced New York Heart Association class III or IV in 15%.
Results of the ACUTE Trial
Only 8 patients experienced a primary outcome and there was no difference in the composite of embolic events for the 2 strategies (0.8% TEE group vs. 0.5% conventional group, p = .50). Table 1 summarizes the major outcomes for the 2 groups. The main difference between the groups was seen in the number of bleeding events with minor and major bleeding seen in 2.9% of patients in the TEE guided group and 5.5% in the conventional group (relative risk 0.53, 95% confidence interval 0.30-0.93, p = 0.03). There were 14 major bleeding events, 10 of which were due to gastrointestinal causes and 8 were associated with a super therapeutic INR level [16] . Other secondary end points including death from all causes, cardiovascular death, functional status assessed by
